Vascular disease retinal

An additional clinical use of acetazolamide is unrelated to its ocular hypotensive properties.The 500-mg acetazolamide capsule administered daily for 2 weeks may produce either a partial or a complete resolution of macular edema in patients with cystoid macular edema (CME), retinitis pigmentosa, and chronic intermediate uveitis (pars planitis). Macular edema produced by primary retinal vascular diseases (branch and central retinal vein occlusion and macular telangiectasia) did not respond to acetazolamide therapy. It is believed that acetazolamide may improve visual function if the macular edema stems from retinal pigment epithelial dysfunction. Improved macular edema in these conditions may be associated with fluid movement from the retina to the choroid. However, acetazolamide does not appear to alter macular blood flow. 

Because the normal blood-retinal barrier resists various substances, including fluorescein, the presence of fluorescein in the vitreous humor indicates a functional breakdown of this barrier. Although physiologic factors and instrument artifacts can influence vitreous fluorescence, this technique has been used to detect retinal vascular disease, especially in diabetes.The procedure has also been used to study the integrity of the blood-retinal barrier in various other diseases, including retinitis pigmentosa, optic neuritis, and essential hypertension. 

CME results from many ocular conditions but is not an independent disease entity. Retinal cell processes in Henle s layer run parallel to the surface of the internal limiting membrane, and the laxity of this layer fc>rms a potential reservoir for extravascular fluid resulting from breakdown of the blood-retinal barrier, which forms extracellular cystoid spaces in the perifoveal area. CME accompanies several retinal vascular diseases, including diabetic maculopathy central retinal venous occlusion, and branch venous occlusion. It may follow surgical procedures, most often cataract extraction and retinal detachment repair, or posterior inflammatory conditions, including pars planitis, chronic uveitis, and miscellaneous conditions such as retinitis pigmentosa. 

Retinal vascular diseases, such as vascular occlusions, hemorrhage, retinal venous thrombosis Retinal hemorrhage... 

Pigmentary changes, color vision loss, visual field defects Visual disturbances, entoptic phenomena RefractUe opacities in posterior pole, macular edema Retinal vascular disease Visual field constriction... 

The use of intravitreal corticosteroids was first popularized by Machemer in 1979 (33) in an effort to halt cellular proliferation after retinal detachment surgery, and Graham (34), McCuen (35), Tano (36), and others have studied its use in both animal models and humans. In contrast to other corticosteroids with short half-lives following intravitreal injection, triamcinolone acetonide is an effective and well-tolerated (35,37) agent for intravitreal injection in conditions such as uveitis (38,39), macular edema secondary to ocular trauma or retinal vascular disease (40), proliferative diabetic retinopathy (41), intraocular proliferation such as proliferative vitreoretinopathy (42), and choroidal neovascularization from AMD (43,44). 

The measurement of retinal blood flow is important, as it provides insight into retinal physiology and leads to better understanding of the onset and progression of retinal vascular diseases that are common causes of vision loss. 

Recently, intravitreal triamcinolone acetonide has been used clinically to treat retinal vascular disease (Fig. 4). A case report by Jonas and Sofker (32) described a patient with nonproliferative diabetic retinopathy and a six-month history of persistent, diffuse macular edema despite grid photocoagulation. Following one intravitreal injection of triamcinolone acetonide, the visual acuity of this patient improved from 20/200 to 20/50 over a five-month follow-up period. It was also noted that there was marked regression of macular edema on clinical examination. Martidis et al. (33,34) reported on the use of intravitreal triamcinolone for refractory diabetic macular edema. Sixteen eyes with a macular thickness of at least 300 pm despite prior photocoagulation were treated with 4 mg injections of triamcinolone. At three-month follow-up the mean decrease in central retinal thickness was 57.5%, with a visual acuity increase of 2.4 Snellen lines. Those with six-month follow-up demonstrated some recurrence of edema and visual acuity improvement was reduced to 1.3 lines. 

This reference studies the most recent advances in the development of ocular drug delivery systems. Covering methods to treat or prevent ocular inflammation, retinal vascular disease, retinal degeneration, and proliferative eye disease, this source covers breakthroughs in the management of endophthalmitis, uveitis, diabetic macular edema, and age-related macular degeneration. 

Improving giycaemic control may not only reduce the rate of non-enzymatic glycosyiation and monosaccharide autooxidation, but lower polyol pathway activity. In addition, it should have a beneficial effect on other haemodynamic and hormonal factors involved in the development of diabetic vascular disease. However, in studies of diabetic retinopathy, rapid control of glucose levels by intensive insulin therapy has been shown to worsen vascular disease initially and it could be postulated that a sudden improvement in retinal blood flow promotes further free-radical damage as part of a reperfusion-ischaemic injury. 

The spirochetes, which have a special morphology consisting of flexible spirals, include Treponema pallidum, which can cause syphilis. Possible syphilitic eye disease findings include interstitial keratitis, uveitis, pigmentary retinopathy, vitritis, retinal vascular sheathing, and papillitis. 

Several extended-release devices able to deliver a consistent level of corticosteroid to the retina have been devised. Two will be presented in this chapter, although other devices are under evaluation or in the development pipeline at the time of writing. The primary indications for these devices are persistent macular edema associated with several conditions, including diabetic retinopathy, retinal vascular occlusive disease, cataract surgery, and posterior uveitis. 

Retinal vascular occlusion is rare, but it can occur in patients with severe vascular disease, without retrobulbar or optic nerve sheath hemorrhage the mechanism is unclear (SED-12, 254) (306). 

Studies 1 Faust and Tyler [315], and by Connell and Kelman [316] have failed to reveal a significantly different incidence of eye abnormalities in pill users. Both groups of workers pointed out the limitations inherent in studies involving relatively small groups of patients. Two cases of retinal oedema secondary to the use of oral contraceptives have been reported by Goren [317], Four cases studied by Salmon, Winkelman and Gay [318] led these authors to the conclusion that neuro-opthalmic sequelae may be secondary to vascular disease. A possible connection between oral contraceptives and ocular complications in users of contact lenses has been mentioned by several workers (see for example [319]). 

---